Solid Q1 2016 growth for Roche

Amy Schofield 20 April 2016

Roche has reported solid sales growth in the first quarter of 2016, with Pharmaceutical Division sales up 4%, driven by oncology and immunology medicines. 

Group sales are also up 4% at constant exchange rates, 5% in Swiss francs, while Diagnostics Division sales grew 5%, led by immunodiagnostic product demand.

The growth in sales in the Pharmaceuticals Division were driven by Perjeta, MabThera and RoActemra. Pharmaceuticals sales in the US increased, led by Esbriet, Xolair and HER2-positive breast cancer medicines. The recently launched medicines Cotellic in skin cancer and Alecensa in lung cancer are reported to be doing well initially. In the US, sales of Tamiflu and Lucentis declined.

The main growth contributors in the International region were Avastin, MabThera and Herceptin at 4%. In Japan, sales rose 4% driven by Avastin, HER2 medicines and Alecensa.

The US FDA has also granted priority review for investigational cancer immunotherapy medicine atezolizumab in advanced bladder cancer and lung cancer and breakthrough therapy designation for ocrelizumab in multiple sclerosis.

Roche CEO Severin Schwan said: “We have started the year with solid growth in both our Pharmaceuticals and Diagnostics Divisions. Overall, we are on track to meet our full-year targets for 2016.”

Roche expects sales to grow at constant exchange rates in 2016. 

Image: Flickr.com

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.